Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

lure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achiev
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DANVERS, Mass. , Aug. 27, 2014 North ... with a prestigious R&D 100 Award for the new OSRAM ... laser and LED-based white light module for microscopy, endoscopy and ... Xenon lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of ...
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... following financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over ... loss for the quarter of $240,156 compared to net income ... For the nine months ended June 30, ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... Medicaid and the State of Alabama are partnering with ... infrastructure for a statewide health information exchange (HIE) that ... (Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO) The partnership is ... diverse group of stakeholders into functional, user-friendly design for ...
... /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" ... medicine and drugs in the People,s Republic of China ("PRC"), ... ended September 30, 2011. Summary financial data is provided below: ... Financial Highlights Revenues for the ...
Cached Medicine Technology:Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange 2Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange 3Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 6
(Date:8/27/2014)... Silver Spring, Md. (PRWEB) August 27, 2014 ... Physicians (CHEST) recently released guidelines for the management ... adults, Pharmacological Therapy for Pulmonary Arterial Hypertension in ... guidelines are free to view for clinicians, and ... for PAH. , The Pulmonary Hypertension Association ...
(Date:8/27/2014)... Dennis Thompson HealthDay ... Someone who has been mugged in a dark alley will ... with a fear of being attacked. But neuroscientists working ... how memories are linked with positive and negative emotions. And ... emotions attached to a memory. In essence, they made ...
(Date:8/27/2014)... Warren, MI (PRWEB) August 27, 2014 Michigan ... to help the children of a local elementary school by ... year. Siersma Elementary School has year-round attendance, and Michigan Head ... equipped to meet the new school year. , "There are ... think this is a great way to give back to ...
(Date:8/27/2014)... August 27, 2014 The federal judge ... ) has extended the deadline for plaintiffs to enroll ... 2014 Order issued by U.S. District Judge David Katz ... enroll in the DePuy ASR Settlement Program must do ... Inc. ASR Hip Implant Products Liability Litigation – MDL ...
(Date:8/27/2014)... (HealthDay News) -- Pouring half a glass of wine at a ... new study. Researchers asked 74 college students and staff to ... that had varying amounts of wine in them. The participants were ... had a "rule of thumb" about how much to pour -- ... from the top -- poured less wine than those without set ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:'Half a Glass' Rule May Curb Overdrinking 2
... Mismatch occurs between seeing letter and the sound it ... -- New brain scans reveal more about how the ... problem seems to be a mismatch between seeing the ... or vice-versa, said researchers from the University of Maastricht ...
... to heart attacks than their predecessors, researchers say , , THURSDAY, ... good shape, even when compared with their counterparts 10 or ... study, more aging boomers are being hospitalized for heart attacks ... the increase in cases could place a big burden on ...
... Shamir Optical Industry Ltd. (Nasdaq: SHMR ) ("Shamir") ... earnings results on Wednesday, March 18, 2009, and has scheduled ... EDT that morning. The conference call will be broadcast live ... www.kcsa.com approximately five minutes before the conference call ...
... MESSA,s East Lansing-based ... consecutive year for superior efficiency and performance in providing ... providing efficient and effective customer service as measured against ... at Purdue University and BenchmarkPortal. "MESSA is ...
... Care Management Software Applications As Part of Electronic ... TCS Healthcare Technologies (TCS), an industry ... applications, supports the health information technology (IT) provisions ... as the American Recovery and Reinvestment Act of ...
... researchers find aerosol levels have diminished visibility , , THURSDAY, ... of data showing how clear, or unclear, the sky ... air pollution have affected climate change, according to a ... show that what the researchers call clear sky visibility ...
Cached Medicine News:Health News:Brain Scans Shed Light on Dyslexia 2Health News:Brain Scans Shed Light on Dyslexia 3Health News:Aging Baby Boomers May Swamp Cardiac Care 2Health News:Aging Baby Boomers May Swamp Cardiac Care 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Fourth Quarter and Year End 2008 Earnings Results 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 3Health News:TCS Healthcare Technologies Offers Health IT Solutions That Support Health Care Reform 2Health News:TCS Healthcare Technologies Offers Health IT Solutions That Support Health Care Reform 3Health News:Clear Skies Have Become Less So Over Time, Data Show 2
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
The VersaFluor cuvette fluorometer is a fast and simple way to quantitate DNA, RNA, and proteins, to detect apoptosis, and to perform reporter enzyme assays with the high level of sensitivity and sel...
... unique microprocessor-controlled filter wheels for wavelength selection ... filter wheels can be programmed for excitation ... With this fluorometer, you do not have ... wavelengths. The C&L Dye Fluorometer can measure ...
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
Medicine Products: